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Abstract
Background: Hepatitis C virus (HCV) is a major health concern with almost 3% of the world’s population (350
million individuals) and 10% of the Pakistani population chronically infected with this viral pathogen. The current
therapy of interferon-a and ribavirin against HCV has limited efficiency, so alternative options are desperately
needed. RNA interference (RNAi), which results in a sequence-specific degradation of HCV RNA has potential as a
powerful alternative molecular therapeutic approach. Concerning viral entry, the HCV structural gene E2 is mainly
involved in virus attachment to the host cell surface receptors i.e., CD81 tetraspanin, scavenger receptor class B
type 1 (SR-B1), low density lipoprotein receptor (LDLR) and claudin1 (CLDN1).
Results: In this report, we studied the relationship of the HCV receptors CD81, LDL, CLDN1 and SR-B1to HCV
infection. The potential of siRNAs to inhibit HCV-3a replication in serum-infected Huh-7 cells was demonstrated by
treatment with siRNAs against HCV receptors, which resulted in a significant decrease in HCV viral copy number.
Conclusions: Our data clearly demonstrate that the RNAi-mediated silencing of HCV receptors is among the first
of its type for the development of an effective siRNA-based therapeutic option against HCV-3a. These findings will
shed further light on the possible role of receptors in inhibition of HCV-3a viral titre through siRNA mediated
silencing.
Introduction
HCV infection is a major health problem; more than
350 million people worldwide and 10% of the population
in Pakistan are chronically infected with this disease
[1,2]. In 40-60% of HCV-infected individuals, chronic
infection is mainly associated with liver cirrhosis and
steatosis, leading to hepatocellular carcinoma (HCC)
[3,4]. In Pakistan, the major HCV genotype is 3a, fol-
lowed by 3b and 1a, with a strong correlation between
chronic HCV infection and HCC in Pakistan associated
with genotype 3a [5]. About 75% of patients achieve no
therapeutic benefit from the present combination therapy
with pegylated interferon a (PEG-IFN-a) and ribavirin
because of adverse side effects [6]. In order to get a better
treatment effect, there is a desperate need to develop
more efficient and better therapeutic alternatives for
treating HCV infections.
The mechanism of HCV cell entry was only revealed
after years of research due to the absence of suitable
animal models and in vitro cell culture systems.
Recently, different groups have studied HCV replication
in serum-infected liver cell lines which mimics the biol-
ogy of the naturally occurring HCV virions biology and
the kinetics of HCV infection in humans liver cells
[7-13]. HCV envelop proteins E1 and E2 are highly gly-
cosylated and have functional roles in protein folding,
HCV entry, fusion and defense against neutralization by
envelope-specific antibodies [14-19]. E2 glycoproteins
take part as key components in the interaction between
the virus and its major cellular receptors like CD81,
SR-BI and CLDN1 [20-22]. HCV enters the cell through
receptors followed by the release of its viral RNA gen-
ome into the cytoplasm. CD81 is a strong candidate to
serve as a HCV cell surface receptor [23-25]. HCV E2
binds with high affinity to the large extracellular loop of
CD81, a tetraspanin found on the surface of different
cell types, including hepatocytes and epithelial cells, and
plays an important role in the early steps of viral entry
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receptor class B type I (SRBI) and low-density-lipopro-
teins receptor (LDLR) [29,30]. SR-BI is thought to be a
putative “post binding” entry molecule of HCV [31,32].
Furthermore, interaction of HCV in association with
lipoproteins and LDLR via nonspecific uptake into hepa-
tocytes is also a possible mechanism of HCV cell entry
[33,34]. Recently, the tight junction protein claudin-1
has also been identified as a late entry factor for HCV
infection [35,36]. Therefore, HCV receptors are a good
target to block HCV entry.
RNA interference (RNAi) is a sequence specific gene
silencing mechanism induced by small interfering RNA
(siRNA) to which HCV RNA is highly susceptible
[37-39]. Currently, research is focused on developing
this sequence-specific gene silencing for human therapy
and gene function studies. Despite the limitation of
sequence variability, the development of an effective
RNAi-based antiviral therapy can be achieved by finding
highly effective target sites and targeting HCV genes
and cellular genes at the same time. Previously, we
reported the development of an siRNA targeting the
HCV-3a envelope proteins crucial for viral entry [40].
This method provides a better choice for development
of a rational antiviral strategy against the local HCV-3a
genotype.
In the present study, the inhibition of HCV entry via
cellular receptors using siRNA against CD81, LDLR, SR-
BI, CLDN1 was observed, which we interpreted as con-
firmation of the role of these receptors in mediating
HCV entry. Moreover, we also showed the effect of
siRNA-induced silencing of receptor genes in reducing
HCV viral load in serum-infected Huh-7 cells.
Materials and methods
Source of samples
he local HCV 1a and HCV-3a patients’ serum samples
used in this investigation were obtained from the
CAMB (Center for Applied Molecular Biology) diagnos-
tic laboratory, Lahore, Pakistan after quantification and
genotype determination. Serum samples were stored at
-80°C prior to RNA extraction for cloning and viral
inoculation experiments. Patients’ written consent and
approval for this study was obtained from our institu-
tional ethical committee.
Design and synthesis of siRNA
Design and synthesis of siRNA was done as described
earlier [12,41,42]. Briefly, siRNA oligonucleotides were
selected to generate RNA interference against HCV
receptors using the Ambion’s siRNA design tool http://
www.ambion.com/techlib/misc/siRNA_finder.html. The
designed siRNAs (cellular genes, HCV receptors and
scrambled control) were synthesized using the Silencer
siRNA construction kit according to the manufacturer’s
instruction (Ambion, USA).
Viral inoculation and co-transfection
with siRNA in Huh-7 cell line
T h eH u h - 7c e l ll i n ew a sk i n d l yp r o v i d e db yD r .Z a f a r
Nawaz (University of Miami, USA) and maintained in
Dulbecco’s modified eagle medium (DMEM) supple-
mented with 100 μg/ml penicillin/streptomycin and 10%
fetal bovine serum (Sigma Aldrich, USA) at 37°C with
5% CO2 as complete medium. The medium was
renewed every 3 days and cells were passaged every 4-5
days. To examine the effects of siRNAs, cells were trans-
fected with siRNAs specific for either HCV receptors or
scrambled HCV serum-infected cells.
The Huh-7 cell line was used to establish the in vitro
replication of HCV-1a and 3a. A similar protocol was
used for viral inoculation as described previously
[11,12,42-44]. Briefly, for these experiments serum from
HCV-3a patients containing a high viral titer (> 1 × 10
8
IU/ml) was used as principle inoculums. Huh-7 cells
were maintained in 6-well culture plates to semi-conflu-
ence, washed twice with serum-free medium then inocu-
lated with 500 μl( 5×1 0
7IU/well viral load) of HCV-3a
sera and 500 μl serum-free media. Cells were main-
t a i n e do v e r n i g h ta t3 7 ° Ci n5 %C O 2. Next day, the
adherent cells were washed three times with 1X PBS,
complete medium was added and incubation was con-
tinued for 48 hrs. Cells were harvested and assessed for
t h ep r e s e n c eo fv i r a lR N Aq u a n t i t a t i v e l yb yr e a l - t i m e
PCR. To analyze the effect of siRNA on HCV infection,
serum infected Huh-7 cells were seeded after three days
of infection in 24-well plates and grown to 80% conflu-
ence with 2 ml medium. The cells were transfected with
or without 40 μM/well siRNA against cellular receptors
alone or in combination using Lipofectamine™ 2000
(Invitrogen Life technologies, CA) according to the
manufacturer’s protocol as described earlier [12,45].
Viral load quantification
Cells were harvested for viral load determination using
the Gentra RNA isolation kit (Gentra System Pennsylva-
nia, USA) according to the manufacturer’si n s t r u c t i o n s .
For viral quantification, the Sacace HCV quantitative
analysis kit (Sacace Biotechnologies Caserta, Italy) was
used. Briefly, 10 μl of extracted viral RNA was mixed
with an internal control provided by Sacace HCV Real
TM Quant kit and subjected to viral quantification
using a real-time PCR SmartCycler II system (Cepheid
Sunnyvale, USA).
Total RNA isolation and gene expression analysis
Total RNA from HCV serum-infected and no infected
cells was isolated using TRIzol reagent (Invitrogen life
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To analyze the effect of siRNA on envelope gene expres-
sion, cDNA was synthesized from 1 μgo ft o t a lR N A
using Superscript III cDNA synthesis kit (Invitrogen life
technologies, CA) and semi-quantitative RT-PCR was
done using primers of HCV receptors, and GAPDH as
control. Quantitative real-time PCR was carried out
using a Real Time ABI 7500 system (Applied Biosystems
Inc, USA) with SYBR green mix (Fermentas Interna-
tional Inc, Canada) as described earlier [12,42,46]. The
relative gene expression analysis was carried out by the
SDS 3.1 software (Applied Biosystems Inc, USA). Each
individual experiment was performed in triplicate.
Western blotting
To determine the effect of siRNAs on HCV E2 protein
expression levels, HCV serum-infected cells were lysed
using the ProteoJET mammalian cell lysis reagent (Fer-
mentas, Canada). Equal amounts of total proteins were
subjected to electrophoresis on 12% SDS-PAGE and
electrophoretically transferred to a nitrocellulose mem-
brane according to the manufacturer’sp r o t o c o l( B i o -
Rad, CA). After blocking nonspecific binding sites with
5% skimmed milk, blots were incubated with primary
monoclonal antibodies specific for HCV E2 and cellular
GAPDH (Santa Cruz Biotechnology Inc, USA) and sec-
ondary horseradish peroxidase-conjugated anti-goat and
anti-mouse antibodies (Sigma Aldrich, USA). The pro-
tein expressions were evaluated using a chemilumines-
cence detection kit (Sigma Aldrich, USA).
Statistical analysis
All statistical analysis was done using SPSS software
(version 16.0, SPSS Inc). Data are presented as mean ±
SD. Numerical data were analyzed using student’st - t e s t
and ANOVA. A p value < 0.05 was considered statisti-
cally significant.
Results
Relative expression analysis of HCV receptor genes in
serum-infected Huh-7 cells
In our previous studies we successfully established HCV
serum infection in Huh-7 cells and monitored viral load
[12,42,47]. In this study, we compared the mRNA
expression of CD81, LDLR, SR-BI and CLDN1 genes in
HCV genotype 1a and 3a serum-infected Huh-7 cells.
HCV serum-infected liver cell lines as model cell culture
system were used to study HCV entry receptors
[7,12,48-51]. Expression of these HCV receptors was
analyzed after total RNA isolation by semi-quantitative
PCR and real-time PCR using gene-specific primers.
Semi-quantitative results indicate the higher expression
of CD81, LDLR, SR-BI and CLDN1 genes in Huh-7 cell
infected with HCV genotype 3a serum as compare to
genotype 1a (Figure 1A). Real-time PCR results indicate
the up regulation of genes in HCV-3a serum infected
Huh-7 cells as CD81 (4.2 fold), LDLR (3.3 fold), SR-BI
( 2 . 3f o l d )a n dC L D N 1( 3f o l d )w h i l ei nH C V - 1 as e r u m -
infected Huh-7 cells the changes were: CD81 (2 fold),
LDLR (1.3 fold), SR-BI (1.2 fold) and CLDN1 (1.4 fold)
compared to normal serum (Figure 1B).
Figure 1 Comparison of expression of CD81, LDLR, SR-BI and CLDN genes in HCV 3a and HCV 1a serum-infected Huh-7 cells. A) Gene
expression of CD81, LDLR, SR-BI and CLDN1genes in Huh-7 infected with HCV serum of genotype 3a (S3a) and HCV serum of genotype 1a (S1a)
as compared to normal serum (NSer). Cells were harvested and relative RNA determinations were carried out using semi-quantitative PCR. B)
Relative gene expression of CD81, LDLR, SR-BI and CLDN1genes in Huh-7 infected with HCV serum of genotype 3a (S3a) and HCV serum of
genotype 1a (S1a) as compared to normal serum (N) by real time PCR. All experiments were performed three times independently with triplicate
samples in each. Error bars indicate the mean plus or minus SD. *p < 0.01 vs. normal
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CD81, LDLR, CLDN and SR-BI genes
siRNA-mediated RNAi is strictly sequence specific, so
appropriately designed siRNAs targeting HCV genomic
RNA can efficiently and specifically suppress HCV repli-
cation in vitro [52-54]. In vitro-transcribed sequence-
specific siRNAs were designed against two regions of
each HCV receptor i.e., siCD81, siCD81-B against
CD81, siLDLR, siLDLR-B against LDLR, siSRBI, siSRBI-
B against SRB1 and siCLDN1, siCLDNI-B against
CLDN1 gene and scrambled (Sc) siRNA. Those which
have been transcribed with nonspecific sequence have
no homology to any known cellular genes. A scrambled
sequence has been used to avoid any changes to the
gene expression that may result from the siRNA delivery
method. Scrambled Sc siRNA serves as a negative con-
trol (Table 1). Huh-7 cells were transfected with 100
nM of each of two siRNAs against each HCV receptor,
then infected with HCV serum of genotype 3a for 48
hrs. Semi-quantitative PCR results showed that using
siRNAs against HCV receptors CD81, LDLR, SR-BI and
CLDN1 in serum-infected Huh-7 cells gave varied
reductions in expression after 48 hr. The CD81 gene
was maximally inhibited bys i C D 8 1 - B ,t h eL D L Rg e n e
by siLDLR, the SR-BI by siSRBI and the CLDN1 gene
by both siCLDN1 and siCLDN1-B as compared to con-
trol (S3a) (data not shown). Therefore, in further experi-
ments for silencing the expression of CD81, LDLR, SR-
BI and CLDN1 genes we used only siCD81-B, siLDLR,
siSRBI and siCLDN1 respectively.
Huh-7 cells were infected with HCV serum of geno-
type 3a (S3a) and treated with or without 25 nM, 50
nM and 100 nM of siRNAs against HCV receptors for
48 hrs post-transfection. Transient transfection of HCV
receptor CD81-B, LDLR, SRBI and CLDN1 siRNAs in
Huh-7 cells showed different effects on receptor RNA
expression levels in a dose-dependent manner; but there
was an optimal dose which showed maximum inhibition
for all receptors with their specific siRNA. Results of
semi-quantitative PCR indicate that expression of the
CD81, LDLR CLDN1, and SRB1 receptor genes was sig-
nificantly reduced at 100 nm siRNA as compare to
scrambled siRNA, which showed no inhibition. Further-
more, real-time PCR results confirmed significant inhibi-
tion of mRNA expression of receptors CD81 (3-fold),
LDLR gene (2-fold), CLDN1 (1-fold)and SR-B1 (0.8-
fold) by using 100nM dose of siRNA against them as
compare to HCV 3a serum infected Huh-7 cells without
siRNA (Figure 2). The results of these dose-dependent
experiments show that the optimal dose of siRNA which
shows best inhibition of receptors is 100 nM for
siCD81-B, siLDLR, siSRBI and siCLDN1. Using the
results of this experiment, we screened the siRNAs
against HCV receptors and selected the optimal dose of
siRNA for further experiments.
Silencing effect of HCV receptors siRNAs against HCV
The cellular genes CD81, LDLR, SR-BI and CLDN1 that
are functionally involved in HCV entry can also serve as
potential targets for RNAi. Several studies have shown
that siRNA against CD81 distinctly inhibited HCV entry
(> 90%) in HCV serum infection irrespective of HCV
genotype, viral load, or liver donor [55]. Furthermore,
90% down-regulation of SR-BI expression was also seen
in Huh-7 cells by RNAi which caused a 30%-90% inhibi-
tion of HCVpp infection [56,57]. Silencing of CLDN1
also inhibited HCV infection in susceptible cells
(Huh7.5) [58]. In the present study, we observed that
sequence-specific siRNAs against the CD81, LDLR, SRBI
and CLDN1 receptors significantly inhibit the expression
of their respective genes. Keeping all this in view, we
used in vitro-transcribed siRNA against all HCV recep-
t o r sC D 8 1 ,S R - B I ,L D L R ,C L D N 1a n do b s e r v e dt h e
effect of silencing of these receptors on viral titer. In the
first step, we analyzed the effect on viral titer by silen-
cing each receptor individually and in combination
using siRNA against two receptors simultaneously. To
determine whether siRNA against each HCV receptor
can reduce viral load in HCV-infected cells, Huh-7 cells
were infected with HCV serum with and without indivi-
dual siRNAs (100 nM) against each HCV receptor,
CD81, LDLR, SR-BI and CLDN1, for 48 hrs. Their RNA
and viral loads were quantified by real-time PCR.
Results showed a 67%, 58%, 35%, and 51% decrease in
viral load incubated with HCV receptor CD81, LDLR,
CLDN1 and SR-BI siRNAs, respectively compared to
Table 1 Sequences of siRNA used in this study
No Name Sequences
1 Scramble-antisense AACCTGCATACGCGACTCGACCCTGTCTC
Scramble-sense AAGTCGAGTCGCGTATGCAGGCCTGTCTC
4 CD81 antisense AAGTGCATCAAGTACCTGCTCCCTGTCTC
CD81 sense AAGAGCAGGTACTTGATGCACCCTGTCTC
5 CD81-B antisense AAGATGCCTACATAGAAGGTGCCTGTCTC
CD81-B sense AACACCTTCTATGTAGGCATCCCTGTCTC
6 LDL antisense AAATGCATCTCCTACAAGTGGCCTGTCTC
LDL sense AACCACTTGTAGGAGATGCATCCTGTCTC
7 LDL-B antisense AACTCCCGCCAAGATCAAGAACCTGTCTC
LDL-B sense AATTCTTGATCTTGGCGGGAGCCTGTCTC
8 SR antisense AAGCAACATCACCTTCAACAACCTGTCTC
SR sense AATTGTTGAAGGTGATGTTGCCCTGTCTC
9 SR-B antisense AACATGATCAATGGAACTTCTCCTGTCTC
SR-B sense AAAGAAGTTCCATTGATCATGCCTGTCTC
10 CLD antisense AATCTGAGCAGCACATTGCAACCTGTCTC
CLD sense AATTGCAATGTGCTGCTCAGACCTGTCTC
11 CLD-B antisense AAGGCATTTGGCTGCTGTAAGCCTGTCTC
CLD-B sense AACTTACAGCAGCCAAATGCCCCTGTCTC
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scrambled control siRNA (Figure 3).
In the second step, to determine whether a combina-
tion of siRNA against respective HCV receptors can
reduce viral load in HCV-infected cells, Huh-7 cells
were infected with HCV serum with or without the fol-
lowing combinations of siRNA at 100nM: CD-81+LDLR,
CD-81+SR-BI, CD-81+CLDN, LDLR+ SR-BI, LDLR+
CLDN, CLDN+SR-BI. At 48 hrs after treatment, the
RNA and viral loads were quantified by real-time PCR.
Results showed 83.5%, 43%, 64.5%, 60%, 73% and 43%
decrease in viral load incubated with siRNA of CD-81
+LDLR, CD-81+CLDN, CD-81+SR-BI, LDLR+ CLDN,
LDLR+ SR-BI, CLDN+SR-BI, respectively as compare to
control (S3a), whereas no inhibition was observed with
scrambled siRNA (Figure 4). The siRNA combinations
of siCD81 + siLDLR and siLDLR+ siSR-BI showed max-
imum inhibition of viral load.
Furthermore, the effect of inhibition of HCV recep-
tor genes CD81, LDLR and SR-B1 on the expression of
Figure 2 Silencing of gene expression of HCV receptors by their specific siRNA in a dose dependent manner. Huh-7 cells were infected
with HCV-3a serum (S3a) along with or without 25 nM, 50 nM and 100 nM of siRNAs against HCV receptors CD81, LDLR, CLDN1 and SR-BI and
scrambled (Sc) siRNA for 48 hrs. The scrambled (Sc) siRNA has nonspecific sequence with no homology to any known cellular genes. A) Semi-
quantitative PCR analysis of gene expression of CD81, LDLR, CLDN1 and SR-BI using serial doses (25 nM, 50 nM and 100 nM) of scrambled siRNA
or the specific siRNA siCD81, siCLDN, siLDLR, or siSR-BI respectively. B) Real-time PCR analysis indicating fold reduction of CD81, CLDN1, LDLR,
and SR-BI gene using serial doses (25 nM, 50 nM and 100 nM) of scrambled siRNA or specific siRNAs of siCD81, siCLDN, siLDLR or, siSR-BI
respectively.
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using specific antibodies. Huh-7 cell lysates infected
with HCV serum of genotype 3a with or without siR-
NAs (100 nM each) against HCV receptors CD81,
LDLR and SR-B1 for 48 hrs were separated by SDS
PAGE and immunoblotted with antibodies specific for
proteins. Results indicate a significant inhibition of
expression of E2 3a, when a combination of siRNA
(siLDLR+siCD81) were used as compare to individual
siRNA against CD81 and LDLR (Figure 5). These
results show the reduced total cellular viral protein
expression due to the low expression of HCV envelop
protein. Similarly, western blotting results indicate the
significant inhibition of expression of LDLR and SR-B1
when a combination of siRNAs (SR-B1 +siLDLR) was
used compared to individual siRNAs against LDLR and
SR-B1 (Figure 5). This also shows the reduced total
cellular viral protein expression due to the low expres-
sion of HCV envelops protein as well as LDLR recep-
tor protein. The siRNA combinations of siCD81 +
siLDLR and siLDLR+ siSR-BI showed maximum inhi-
bition of viral envelope protein E2, which confirms the
inhibition of HCV infection seen with siRNAs against
HCV receptors
Discussion
HCV entry into hepatocytes is the first step in the virus
life cycle that results in productive viral infection, pro-
viding a major target for immunopreventive and thera-
peutic strategies [59-61]. Viral entry is thought to be
mediated by HCV envelop glycoproteins E1 and E2 and
several cell surface receptors which facilitate the binding
of virus to host cells; but none of these cell surface fac-
tors alone are responsible for promoting HCV entry.
Figure 3 Effect of silencing of HCV receptors by their specific
siRNA on viral titer in Huh-7 cells. A) Viral titer in Huh-7 cells
treated with scrambled siRNAs (Sc) or siRNAs of CD-81, LDL, SR and
CLD and incubated for 6 hrs before adding HCV-3a sera (Ser 3a).
HCV RNA levels were quantified by real-time PCR. Data are
expressed as mean percent viral load of non-siRNA treated samples.
Three independent experiments with triplicate determinations were
performed. Error bars indicate, means plus or minus SD. *p < 0.01
vs. Ser3a.
Figure 4 Combined effect of specific siRNA silencing of HCV
receptors on viral titer in Huh-7 cells. Huh-7 cells were treated
with scrambled siRNAs (Sc) or combinations of siRNAs (siCD81-B
+siLDLR, siCD81+siCLDN1, siCD81+siSR-BI, siLDLR+ siCLDN1, siLDLR+
siSR-BI, siCLDN1+siSR-BI) and incubated for 6 hrs before adding
HCV-3a sera (Ser 3a). HCV RNA levels were quantified by real-time
PCR. Data are expressed as mean percent viral load of non-siRNA
treated samples. Three independent experiments with triplicate
determinations were performed. Error bars indicate indicate means
plus or minus SD. *p < 0.01vs. Ser3a.
Figure 5 Analysis of HCV E2 protein expression by using siRNA
alone and in combination against HCV receptor genes CD81,
LDLR and SR-B1. Protein was isolated from Huh-7 cells treated with
single or combinations of siRNA (siCD81-B, siLDLR and siSR-B1)
against HCV receptor CD81 LDLR and SR-B1 genes and incubated
for 6 hrs before adding HCV-3a sera (Ser 3a) for 48 hrs. Protein
levels were quantified by western blot analysis using antibodies
specific for E2 and GAPDH. A) Silencing of CD-81 and LDLR genes
alone or in combination using specific siRNAs (siCD81-B, siLDLR)
reduced HCV E2 protein expression levels in Huh-7 cells. B)
Silencing of the LDLR gene or SR-B1 gene alone and in
combination, using specific siRNA (siLDLR, siSR-BI, siCLDN1+siSR-BI)
reduced HCV E2 protein expression in Huh-7 cells. GAPDH protein
levels are also shown as an internal control and scramble siRNA (Sc)
as siRNA control.
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cells leading to the internalization of virus is considered
a multistep process. These cell surface receptors mainly
include the tetraspanin proteins CD81, SR-BI, and
LDLR and the tight junction protein CLDN1 [62-66]. In
this study, we have targeted HCV host cell surface
receptors that interact with HCV structural genes caus-
ing HCV infection. Moreover, we analyzed the effect of
siRNAs separately and in combination against HCV
receptors on viral entry by quantifying the viral titer in
siRNA-treated and non-treated serum-infected Huh-7
cells.
HCV envelop protein E2 posses glycosylation sites
which interact directly with the cell surface receptors
CD81, SR-BI and CLDN1 [67-69], confirming their role
in HCV entry by using HCVpp or HCVcc infection in
liver cell lines [70-73]. Nevertheless, the cell entry prop-
erties of HCVpp and HCVcc are different from those of
serum-derived HCV because they are not associated
with lipoproteins as is HCV naturally present in serum
and do not employ LDLR for their entry into the cell
[74-76]. These experimental models do not mimic the
natural infection process, whereas recent investigations
using serum-derived HCV (HCVser) infection of the
human hepatoma cell line (Huh-7) are consider to reca-
pitulate the in vivo situation as closely as possible [77].
We have described successful HCV serum infection in
liver cells in our earlier studies [12,78,79]. In this study,
we again utilized the serum-infected Huh-7 cell culture
model to evaluate the comparative gene expression
levels of CD81, SR-BI, LDLR and CLDN1 receptors
induced by HCV serum of genotype 1a and 3a. Our
results showed relatively high expression of CD81, SR-
BI, LDLR and CLDN1 receptors in HCV serum-infected
Huh-7 cells of HCV genotype 3a as compared to geno-
type 1a (Figure 1). This information revealed that active
infection by serum-derived HCV particles in Huh-7 cells
contributed to increased expression levels of these cell
surface receptors during infection. Moreover, compara-
tive studies of HCV 1a versus 3a serum infection of
human hepatocytes suggests that the nature of cell-vir-
ion genotype combination is also a determinant factor
for virus entry as both HCV genotypes induced different
expression levels of cell surface receptors.
RNAi provides an exciting new technology that pro-
mises to be useful in treatment of viral diseases. Pre-
viously it has been reported that cellular genes
functionally involved in HCV entry like CD81, LDLR,
SR-BI and CLDN1 also serve as potential targets for
RNAi. Several reports showed that potent RNAi against
HCV gene activity reduced the serum infection 30%-
90% [80-82]. Previously, we have shown the inhibition
of HCV replication and HCV infection in liver cell lines
by using siRNA against HCV structural genes Core,
Envelop E1, E2 and cellular gene Cox-2 in liver cells
[12,42,83]. In the current project, we utilized a similar
RNAi strategy to silence the expression of HCV receptor
genes to block the HCV entry in a serum-derived HCV-
infected Huh-7 cell culture model and analyzedits effect
on viral load. Assessment of the optimum dose regime
of siRNA is essential to enhance the inhibition of target
genes and to better make use of the knockdown
mechanism while limiting off target effects [84]. Serial
doses (25 nM, 50 nM, 100 nM) of siRNA transfected
into Huh-7 cells were used with subsequent HCV 3a
serum infection (Figure 2). Initially, two regions of each
receptor were selected, and among these the most effec-
tive ones were transfected (100 nM) into Huh-7 cells
infected with HCV serum of genotype 3a for further
analysis. The HCV infection pathway employs enhance-
ment in expression of cell surface receptors that may
facilitate entry and increase viral load during infection.
In experiments to knock down the expression of host
cell surface HCV receptors on Huh-7 cells using siRNA
to block HCV entry against each receptor gene sepa-
rately and in combination prior to infection with HCV
serum of genotype 3a, the viral titer was detected by
real-time PCR using primers against the 5 UTR of viral
copies in cells from the fifth day post infection. Our
results indicate a significant decrease in HCV viral load
by 67% and 58% due to the silencing of HCV receptor
CD81 (33 fold) and LDLR (42 fold) respectively when
compared to control (S3a), whereas siSRBI and
siCLDN1 showed comparatively less inhibition of viral
load (Figure 3). Furthermore, HCV viral load was signifi-
cantly decreased up to 84% with combinations of siR-
NAs due to the silencing of siCD81+siLDLR gene and
siLDLR+SRBI as compared to other combinations of
siRNA (Figure 4). These observations confirmed that
CD81 and LDLR are putative receptors facilitating HCV
infection cooperatively, which may play different roles
during the course of infection. Moreover, different stu-
dies exhibit the feasibility of targeting host cell factors
involved in infection, as they are not prone to muta-
tions, as potential targets for siRNA therapy. Henry and
colleagues [85], targeted the IRES, NS5B, and host cell
receptor CD81 by using a triple shRNA expression vec-
tor which concurrently reduced the HCV replication,
CD81 expression, and E2 binding. Targeting multiple
sites of the HCV genome and host factors involved in
HCV infection are a realistic and valid approach aimed
at preventing the virus from developing resistance.
In summary, our data show that siRNAs specific for
HCV cellular receptors not only reduce the receptor
gene expression but also reduce viral titer and viral pro-
tein E2 in siRNA treated cells confirming their role in
HCV infection. A combination of these siRNA (siCD81-
B, siLDLR, SR-BI) showed an even more dramatic
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we propose that the use of siRNAs to inhibit expression
of HCV receptor proteins separately or in combination
could be helpful in reducing HCV entry.
Abbreviations
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